When it comes to cell-based therapy manufacturing, the concept of quality management carries important distinctions from more traditional therapeutics production.
So far, advanced therapy developers have been focusing on partnerships with specific hospitals for collecting patient cellular materials, and there are long-term concerns over the ability f
One key aspect of the biospecimen market (if not the most important) is the availability and accessibility of the donor pool for testing of both normal, healthy donors and disease state don